RE: B pharma” interest “17 Feb 2023 18:50
From Myles M note.
Reality is …
Phase 1 / 2 acquisitions:
- Gilead acquires Forty Seven for $4.9 billion
In March 2020, Gilead agreed to acquire Forty Seven for $4.9bn in cash. Forty Seven’s investigational lead product candidate, magrolimab, is a monoclonal antibody therapy targeting the CD47 protein overexpressed on the surface of many types of cancer cells (i.e. an immunotherapy). At the time of the acquisition announcement, magrolimab was in the middle of a Phase 1b clinical trial.
- Merck acquires VelosBio for $2.8 billion
In November 2020, Merck announced that it would be acquiring VelosBio for $2.75bn in cash. At the time, VelosBio’s lead investigational candidate – VLS-101, an antibody-drug conjugate targeting ROR1 – was being evaluated in Phase 1 and Phase 2 clinical trials for the treatment of patients with haematological malignancies and solid tumours, respectively. [The P2 trial had commenced only in October 2020.]
- Boehringer Ingelheim acquires NBE Therapeutics for €1.2 billion
In December 2020, Boehringer Ingelheim announced that it would be acquiring NBE-Therapeutics for €1.18bn. NBE-Therapeutics’s lead compound, an antibody-drug conjugate named NBE-002, was in the middle of a Phase 1 clinical trial.
- Pfizer acquires Trillium Therapeutics for $2.3 billion
In August 2021, Pfizer agreed to acquire Trillium Therapeutics for $2.26bn in cash. Trillium had two lead candidates – both next-generation, investigational immuno-therapeutics for haematological malignancies – in Phase 1b/2 trials. The target launch date for both drugs (assuming successful clinical development) is 2026.
26
- Bristol Myers Squibb acquires Turning Point Therapeutics for $4.1 billion
In June 2022, BMS agreed to acquire Turning Point Therapeutics for $4.1bn in cash. Turning Point was a precision oncology company. Its lead asset, repotrectinib, is a next-generation, potential best-in-class tyrosine kinase inhibitor targeting the ROS1 and NTRK oncogenic drivers of non-small cell lung cancer and other advanced solid tumours. At the time of the acquisition announcement, repotrectinib had already been granted three Breakthrough Therapy Designations from the US FDA. It was midway through a P1/2 clinical Trial.
Sign In
Follow the stocks
